The PandaOmics platform of Insilico Medical, a clinical-stage generative AI-powered drug discovery business, now includes sophisticated AI chat capabilities. This functionality is based on recent developments in big language models. With the use of the new “ChatPandaGPT” function, researchers are now able to communicate with the platform in normal language while quickly navigating through massive datasets and analyzing them. This makes it easier to identify possible treatment targets and biomarkers. The first biotech business to use massive language models for chat functionality in their AI drug discovery platform is Insilico Medical.
By combining omics data analysis with historical data from publications, clinical trials, and grant applications, PandaOmics, an AI-driven target discovery platform created by Insilico Medical, uses deep learning models to identify therapeutic targets linked to a given condition. By scoring findings on elements like originality, confidence, commercial tractability, druggability, safety, and other crucial characteristics that influence target selection decisions, the system optimizes for the best possible therapeutic targets.
A transformer-based knowledge graph was added to PandaOmics by Insilico Medical in November 2022. The “transformer,” a neural network with specialized architecture, pulls the pertinent data from a list of scientific papers and creates a visually appealing graph that connects genes, illnesses, substances, and biological processes. The knowledge graph provides information on the biological functions of genes and substances in relation to diseases as well as the molecular mechanisms of diseases. Also, it identifies the most promising biomarkers and therapeutic targets.
The knowledge graph functionality of PandaOmics has been integrated with the new chat functionality, which is based on large language models. It provides a more effective, precise, and individualized way to access information on molecular biology, therapeutic target discovery, and pharmaceutical development.
Over and above the standard features of general-purpose chat models, ChatPandaGPT adds additional functionalities. It makes use of a specific knowledge base to deliver precise and thorough information about molecular biology, therapeutic target research, and pharmaceutical development. It employs both natural language processing and machine learning algorithms, enabling it to give platform users more individualized and pertinent responses. ChatPandaGPT is always accessible and capable of handling several enquiries at once without growing weary or making mistakes.
Insilico Medicine’s founder and CEO, Alex Zhavoronkov, PhD, expressed excitement about incorporating this cutting-edge chat functionality into its PandaOmics platform. We’re making it simpler to explore complex data and find possible treatment targets and biomarkers by enabling researchers to have natural language dialogues with the platform.
PandaOmics is well-known for its sophisticated knowledge graph analytics technology, which enables customers to glean linkages and key insights from large, intricate data sets. Users can examine data in a way that is even more naturally and effectively by incorporating the most recent developments in massive language models.
Frank Pun, PhD, the leader of the PandaOmics application scientists team, said, “We’re excited to add this sophisticated chat capabilities into PandaOmics. “This integration represents a significant advancement in our efforts to equip researchers with the resources they require to contribute to substantial advances in the field of drug development.”
Now that ChatPandaGPT and PandaOmics have been integrated, researchers may more quickly and easily navigate through big datasets and conduct analyses on them.
